levosimendan
TNX-103 Small Molecule Target: K-ATP channels, troponin C
Tenax Therapeutics
Most recent annual filing: 2026-03-10
- TNX-103 toplineAug 2026TNX-103 topline, Aug 2026, thesis-defining
- LEVEL Phase 3 levosimendan oralAug 2026LEVEL Phase 3 levosimendan oral, Aug 2026, notable
- TNX-103 enrollment doneend of 2027TNX-103 enrollment done, end of 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
levosimendan
TNX-102Discontinued (1)
- imatinib — Pulmonary Arterial Hypertension · deprioritized the planned Phase 3 clinical trial of imatinib; no significant imatinib development activities ongoing
Biotech Distilled coverage (5)
- 2026-08-11 UPDATE: Tenax Therapeutics (TENX) - The Coin Landed Tails
- 2026-07-31 UPDATE: Tenax Therapeutics (TENX) - The 2030 Cliff Just Moved to 2035 🔒 Paid
- 2026-07-08 UPDATE: Tenax Therapeutics (TENX) - Fidelity Shows Up at 14.9% 🔒 Paid
- 2026-07-02 Tenax Therapeutics (TENX) — Scientific Deep Dive for TNX-103 and Pipeline Products 🔒 Paid
- 2026-07-02 UPDATE: Tenax Therapeutics (TENX) - The Clock Just Got a Date on It 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.